Lexaria Bioscience Corp. Insider Trading

LEXX

⊜ Compare

Last 12 months

No open-market buying or selling by insiders.

The last open-market buy by an executive or director was in Jul 2025.

Net open-market

0 buys · 0 sales

Under a 10b5-1 plan

—

no sales

Insiders who bought / sold

0 / 0

executives and directors

Last open-market buy

Jul 2025

Jul 30, 2025

Get an email when LEXX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jul 29, 2025 – Jul 30, 2025	Christopher Bunka Director	Bought 2 parts	27,500	$0.92 average	25K	3.1%	Form 4
Jul 29, 2025	William Edward McKechnie Director	Bought	5,000	$0.91	5K	38%	Form 4
Jul 29, 2025	John Martin Docherty President & CSO	Bought	5,376	$0.93	5K	9.9%	Form 4
Jul 29, 2025	Vanessa Carle Secretary	Bought	750	$0.91	$683	New	Form 4
Jul 29, 2025	Richard Christopher Chief Executive Officer	Bought	15,000	$0.91	14K	30%	Form 4
Dec 2, 2024 – Dec 3, 2024	Richard Christopher Chief Executive Officer	Bought 2 parts	50,000	$2.36 average	118K	New	Form 4

Jul 29, 2025 – Jul 30, 2025
Christopher Bunka
Director · bought 27,500 at avg $0.92
25K
3.1% of stake
Jul 29, 2025
William Edward McKechnie
Director · bought 5,000 at $0.91
5K
38% of stake
Jul 29, 2025
John Martin Docherty
President & CSO · bought 5,376 at $0.93
5K
9.9% of stake
Jul 29, 2025
Vanessa Carle
Secretary · bought 750 at $0.91
$683
New position
Jul 29, 2025
Richard Christopher
Chief Executive Officer · bought 15,000 at $0.91
14K
30% of stake
Dec 2, 2024 – Dec 3, 2024
Richard Christopher
Chief Executive Officer · bought 50,000 at avg $2.36
118K
New position

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch LEXX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with LEXX

CompareIntrinsic value

BIXTBioxytran Inc.

$0.02-2.84%25

CLNNClene Inc.

$4.10+8.75%0

LIXTLixte Biotechnology Holdings Inc.

$3.60+2.27%10

NXTSNexentis Technologies Inc.

$0.56-2.46%20

PLPLPlandai Biotechnology Inc.

$0.00+0.00%30

RGBPRegen Biopharma Inc.

$0.00-33.33%25

SERSerina Therapeutics Inc.

$1.69-7.65%40

HINDVyome Holdings, Inc

$1.74-1.92%20

Spot a number that looks wrong? Check it in LEXX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing LEXX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.